S evere acute respiratory failure is the dominant cause of death in patients with coronavirus disease 2019 (CO-VID-19) (1). The pathophysiology and imaging features of severe COVID-19 pneumonia have been the focus of considerable interest from the outset of the pandemic. In early disease, widespread ground-glass opacification predominates at thoracic CT (2-6) and is supposedly associated with highly compliant lungs and disrupted vasoregulation (7). Vascular dysregulation is believed to be consequence of exaggerated activation of inflammatory and coagulation cascades (termed immunothrombosis) (1,(8)(9)(10)(11)(12). Later in the course of disease, CT more commonly shows consolidation and fibrosis associated with lower lung compliance (13).There is growing evidence from radiologic and pathologic studies of a significant vasculopathy in COVID-19 pneumonia (14-17); in a recent study of postmortem lungs in COVID-19, there were widespread microthromboses and striking new vessel formation (16). Furthermore, based on qualitative analyses, a number of studies have highlighted the potential role of dual-energy CT pulmonary angiography (DECTPA) (15,(18)(19)(20)(21). Accordingly, in the present study, we aimed to evaluate the relationships between a quantitative measure of perfusion at DECTPA (relative perfused blood volume [PBV], ie, PBV relative to pulmonary artery enhancement [PBV/PAenh]) ( 22) and (a) disease duration, (b) right ventricular dysfunction (RVD) at echocardiography, (c) d-dimer levels, and (d) obstruction score (23) in patients with severe COVID-19 pneumonia. A secondary aim was to compare PBV/PAenh in COVID-19 pneumonia to that of healthy volunteers.